Literature DB >> 14575057

Effect of nebulized furosemide in terminally ill cancer patients with dyspnea.

Hiroyuki Kohara1, Hiroshi Ueoka, Keisuke Aoe, Tadashi Maeda, Hiroyasu Takeyama, Ryusei Saito, Yasuo Shima, Yosuke Uchitomi.   

Abstract

We evaluated the effect of ultrasonically nebulized furosemide (20 mg) on dyspnea uncontrollable by standard therapy in patients with terminal cancer. Dyspnea was evaluated using the Cancer Dyspnea Scale (CDS) before and 60 min after inhalation. Changes in arterial blood gases, hemoglobin oxygen saturation (SpO2), heart rate (HR), and respiratory rate (RR) also were evaluated. In 12 of 15 patients (80%), total dyspnea scores by CDS improved significantly after inhalation of furosemide (P = 0.007), especially concerning a reduced sense of effort (P = 0.013) and reduced anxiety (P = 0.04). No significant changes were observed in the partial pressure of oxygen in arterial blood (PaO2), the partial pressure of carbon dioxide in arterial blood (PaCO2), SpO2, HR, or RR. Inhalation of nebulized furosemide appears to be effective against dyspnea in terminally ill cancer patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575057     DOI: 10.1016/s0885-3924(03)00322-1

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  9 in total

Review 1.  Dyspnea review for the palliative care professional: treatment goals and therapeutic options.

Authors:  Arif H Kamal; Jennifer M Maguire; Jane L Wheeler; David C Currow; Amy P Abernethy
Journal:  J Palliat Med       Date:  2012-01       Impact factor: 2.947

2.  Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness.

Authors:  Robert B Banzett; Richard M Schwartzstein; Robert W Lansing; Carl R O'Donnell
Journal:  Respir Physiol Neurobiol       Date:  2017-08-24       Impact factor: 1.931

3.  The Effect of Aerosol Saline on Laboratory-Induced Dyspnea.

Authors:  C R O'Donnell; R W Lansing; R M Schwartzstein; Robert Banzett
Journal:  Lung       Date:  2016-12-21       Impact factor: 2.584

4.  Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness.

Authors:  Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2017-10-12       Impact factor: 1.931

5.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

6.  Patients' experience of oxygen therapy and dyspnea: a qualitative study in home palliative care.

Authors:  Darin Jaturapatporn; Erica Moran; Chris Obwanga; Amna Husain
Journal:  Support Care Cancer       Date:  2010-03-21       Impact factor: 3.603

7.  An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide.

Authors:  Phillip J Newton; Patricia M Davidson; Christine Sanderson
Journal:  BMC Palliat Care       Date:  2012-04-30       Impact factor: 3.234

8.  Fooling the brain to alleviate dyspnoea.

Authors:  Capucine Morélot-Panzini
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

9.  The efficacy of nebulized furosemide and salbutamol compared with salbutamol alone in reactive airway disease: a double blind randomized, clinical trial.

Authors:  Kambiz Masoumi; Arash Forouzan; Maryam Haddadzadeh Shoushtari; Samaneh Porozan; Maryam Feli; Mehdi Fallah Bagher Sheidaee; Ali Asgari Darian
Journal:  Emerg Med Int       Date:  2014-04-27       Impact factor: 1.112

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.